JACQUELYN LANE: Open Payments
NPI 1871567776 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,917 in 86 payments from 12 companies in 2025. Trend: 2023 $602 · 2024 $1,479 · 2025 $1,917
Food & beverage: $1,917
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $581 |
| Madrigal Pharmaceuticals | 9 | $293 |
| Phathom Pharmaceuticals, Inc. | 6 | $211 |
| Lilly USA, LLC | 7 | $196 |
| Regeneron Healthcare Solutions, Inc. | 7 | $179 |
| Ardelyx, Inc. | 11 | $171 |
| GENZYME CORPORATION | 4 | $138 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $65 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
Products named: DUPIXENT, REZDIFFRA, RINVOQ, VOQUEZNA, OMVOH, IBSRELA, CREON, XIFAXAN.
Industry payments across TX — which companies pay providers there.
